Iron deficiency is common, but persistent low ferritin is rarely
explained by a single factor. The gut environment matters, yet the
microbiome should be considered within a broader hematological and
gastrointestinal evaluation.
Iron deficiency is the most common nutrient deficiency
worldwide. However, I see some patients struggle to rebuild
their iron stores despite supplementation and dietary changes.
When ferritin remains low, the question is not simply how much
iron is being consumed. Persistent iron deficiency is usually
multifactorial and may reflect continued blood loss, inadequate
replacement, poor tolerance or adherence, impaired absorption,
medication effects, increased physiological requirements, or
underlying GI disease.
The GI environment matters,
but the microbiome should be considered one part of a broader
investigation rather than the default explanation.
Ferritin: Useful but Only in Context
Serum iron reflects circulating iron at a particular moment and
can vary considerably. Ferritin is generally a more useful
marker of iron stores, particularly when interpreted alongside
the complete blood count, transferrin saturation, and clinical
context.
Ferritin is also an acute-phase reactant, meaning its level can
change in response to inflammation, tissue injury, or infection.
Inflammation can raise ferritin, potentially masking depleted or
poorly available iron stores. When inflammation or chronic
disease is suspected, I interpret ferritin alongside markers
such as C-reactive protein (hs-CRP or CRP), erythrocyte
sedimentation rate (ESR), and transferrin saturation. Fecal
calprotectin may be appropriate when symptoms suggest
inflammatory bowel disease or other inflammatory GI issues.
Symptoms such as fatigue, reduced exercise tolerance, hair
shedding, restless legs, impaired concentration, or
breathlessness may prompt testing, but they are not specific to
iron deficiency. The laboratory pattern, trends, and underlying
cause still need to be established.
Absolute and Functional Iron Deficiency
An important distinction is the difference between absolute and
functional iron deficiency.
In absolute iron deficiency, the body's iron stores are
genuinely depleted. Ferritin is usually low. Common causes
include menstrual or gastrointestinal blood loss, pregnancy or
increased physiological requirements, insufficient dietary iron,
frequent blood donation, celiac disease or other malabsorption
disorders, H. pylori infection, IBD, gastric or bariatric
surgery, and inadequate or poorly tolerated supplementation.
Functional iron deficiency is different. Iron may still be
present in storage, but inflammation limits its release and
availability to tissues.
The Role of Hepcidin
Hepcidin is a liver-derived hormone that regulates systemic iron
absorption and distribution. When hepcidin rises, it reduces
intestinal iron absorption and restricts the release of stored
iron into the circulation.
Inflammatory cytokines, particularly interleukin-6, can increase
hepcidin production. This helps explain why chronic inflammatory
disorders may produce low circulating iron and low transferrin
saturation despite normal or elevated ferritin.
Inflammation can therefore impair the response to oral iron.
However, persistently low ferritin generally indicates depleted
iron stores and should not be attributed to hepcidin alone.
Ongoing blood loss, inadequate intake, impaired absorption,
treatment tolerance, and adherence must remain central to the
evaluation.
The Bidirectional Gut-Iron Relationship
The relationship between iron and the intestinal microbiome is
complex and bidirectional.
Iron is absorbed primarily in the duodenum and proximal small
intestine. The iron that is not absorbed continues into the
colon, where it becomes available to intestinal microorganisms.
Changes in luminal iron availability may influence microbial
composition, while both iron deficiency and oral iron
supplementation have been associated with changes in the gut
microbiome in some studies.
Human research has reported associations between iron deficiency
and differences in microbial composition, altered abundance of
specific bacterial groups, changes in microbial metabolites,
reduced abundance of some short-chain-fatty-acid-producing
organisms, and intestinal inflammation in certain populations.
These observations are biologically plausible, but they do not
yet establish whether dysbiosis causes refractory iron
deficiency, results from iron deficiency, reflects the
underlying disease, or develops partly in response to iron
treatment. This distinction matters clinically. A stool
microbiome pattern cannot currently explain, by itself, why a
patient's ferritin remains low.
Butyrate and Intestinal Health
Butyrate is a short-chain fatty acid (SCFA) produced by the
fermentation of dietary fiber. It supports colonocyte metabolism,
intestinal barrier integrity, and several anti-inflammatory
pathways.
A reduction in butyrate-producing organisms may indicate an
altered colonic ecosystem. However, dietary iron is absorbed
mainly in the proximal small intestine rather than the colon.
Low fecal butyrate should therefore not be interpreted as direct
evidence of impaired iron absorption.
It may be more appropriate to view low butyrate or reduced
microbial diversity as contextual findings that could reflect
diet, medication exposure, altered motility, inflammation, or
gastrointestinal disease. Their independent role in persistent
iron deficiency remains uncertain.
Practical Evaluation
When ferritin does not improve as expected, the initial
evaluation should return to the fundamentals.
First, I confirm the pattern by reviewing the complete blood
count and red-cell indices, ferritin, serum iron, transferrin
saturation, inflammatory markers when indicated, and the change
in hemoglobin and ferritin over time. In inflammatory
conditions, ferritin may need to be interpreted differently and
in combination with other iron markers.
Then, I review the replacement strategy. This includes the iron
formulation, frequency and duration of treatment,
gastrointestinal tolerance, adherence, concurrent medications or
supplements that may interfere with absorption, and whether the
patient has a condition in which oral iron is unlikely to be
adequately absorbed.
Failure to respond to oral iron does not necessarily mean that
iron deficiency is absent. It may indicate continued losses,
malabsorption, inflammation, poor tolerance, or the need to
consider intravenous replacement, which is outside my scope. I
refer to a hematologist when intravenous replacement is being
considered.
Then, I look for ongoing iron loss. Depending on age, sex,
symptoms, and clinical risk, this may include assessment for
heavy or prolonged menstrual bleeding, occult gastrointestinal
bleeding, blood donation, urinary blood loss, recent surgery,
childbirth, or other sources of blood loss. Unexplained
iron-deficiency anemia in men and postmenopausal women requires
particular attention to gastrointestinal pathology.
Finally, I assess for malabsorption and gastrointestinal
disease. Relevant considerations include celiac disease, H.
pylori, IBD, atrophic gastritis, previous gastric or bariatric
surgery, persistent diarrhea, unexplained abdominal symptoms,
reduced gastric acidity, acid-suppressing medication, and
small-bowel disease when suspected.
The exact investigation is always guided by the patient's
presentation and conventional GI assessment. I also work with
board-certified GI doctors; that is part of what integrative
medicine is about.
What About Stool Testing?
Fecal calprotectin is a clinically established marker of
intestinal inflammation and may help determine whether IBD or
another inflammatory process requires further evaluation.
However, findings such as secretory IgA, fecal short-chain fatty
acids, microbial diversity scores, and dysbiosis indicators are
not officially validated as diagnostic explanations for iron
deficiency.
A stool test may provide exploratory information about the
intestinal ecosystem, but it should not replace evaluation for
bleeding, celiac disease, H. pylori, IBD, malabsorption, or
inadequate iron replacement.
At present, there is no single stool microbiome profile that
reliably identifies the cause of persistent low ferritin or
determines the appropriate iron treatment.
GLP-1 and GIP/GLP-1 Therapies
These therapies introduce additional nutritional considerations.
They may reduce appetite and overall food intake. Nausea,
vomiting, constipation, altered food preferences, and reduced
dietary variety can further limit iron intake in some
individuals. Delayed gastric emptying and other changes in
gastrointestinal physiology may also affect nutritional status.
Emerging observational evidence suggests that iron depletion may
occur in some patients using these therapies, but causality
remains uncertain. Microbiome changes have been proposed as one
possible mechanism, although this remains hypothetical and is
not established as a routine clinical explanation.
When ferritin declines during incretin-based therapy, assessment
should begin with total food and protein intake, dietary iron
sources, the pace and magnitude of weight loss, GI adverse
effects, menstrual and bleeding history, complete blood count,
iron studies, and conventional evaluation for malabsorption or
gastrointestinal disease when indicated.
Stool microbiome testing should not be used as a substitute for
this assessment. To learn more about stool testing in context, I
recommend Biomology.com.
Conclusion
Iron deficiency is rarely explained by a single factor.
The first priority is to confirm true iron deficiency, determine
whether supplementation has been adequate, and check for
continued blood loss, reduced intake, malabsorption, medication
effects, inflammation, and other GI disease.
The gut microbiome is likely involved in iron metabolism, and
iron status can itself influence the intestinal ecosystem. Oral
iron may also alter the microbial environment because much of
the administered iron remains unabsorbed.
However, the clinical implications of these interactions are
still emerging. Microbiome findings should currently be treated
as complementary and exploratory, not as proof of the cause of
persistent low ferritin.
A precise, individualized approach begins with established
hematological and gastrointestinal evaluation.
Microbiome-informed strategies may eventually refine that
approach, but they should build on, rather than replace, the
fundamentals of iron-deficiency care.
To learn more about interpreting lab testing in context, I
recommend
LabNodes.
